These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 23843040)

  • 1. RRM1 domain of the splicing oncoprotein SRSF1 is required for MEK1-MAPK-ERK activation and cellular transformation.
    Shimoni-Sebag A; Lebenthal-Loinger I; Zender L; Karni R
    Carcinogenesis; 2013 Nov; 34(11):2498-504. PubMed ID: 23843040
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activation of the RAF/mitogen-activated protein/extracellular signal-regulated kinase kinase/extracellular signal-regulated kinase pathway mediates apoptosis induced by chelerythrine in osteosarcoma.
    Yang R; Piperdi S; Gorlick R
    Clin Cancer Res; 2008 Oct; 14(20):6396-404. PubMed ID: 18927278
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatocyte growth factor enhances alternative splicing of the Kruppel-like factor 6 (KLF6) tumor suppressor to promote growth through SRSF1.
    Muñoz Ú; Puche JE; Hannivoort R; Lang UE; Cohen-Naftaly M; Friedman SL
    Mol Cancer Res; 2012 Sep; 10(9):1216-27. PubMed ID: 22859706
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Splicing factor hnRNP A2 activates the Ras-MAPK-ERK pathway by controlling A-Raf splicing in hepatocellular carcinoma development.
    Shilo A; Ben Hur V; Denichenko P; Stein I; Pikarsky E; Rauch J; Kolch W; Zender L; Karni R
    RNA; 2014 Apr; 20(4):505-15. PubMed ID: 24572810
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Resistance to mitogen-activated protein kinase kinase (MEK) inhibitors correlates with up-regulation of the MEK/extracellular signal-regulated kinase pathway in hepatocellular carcinoma cells.
    Yip-Schneider MT; Klein PJ; Wentz SC; Zeni A; Menze A; Schmidt CM
    J Pharmacol Exp Ther; 2009 Jun; 329(3):1063-70. PubMed ID: 19258520
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ERK signalling and oncogene transformation are not impaired in cells lacking A-Raf.
    Mercer K; Chiloeches A; Hüser M; Kiernan M; Marais R; Pritchard C
    Oncogene; 2002 Jan; 21(3):347-55. PubMed ID: 11821947
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The second RNA-binding domain of the human splicing factor ASF/SF2 is the critical domain controlling adenovirus E1A alternative 5'-splice site selection.
    Dauksaite V; Akusjärvi G
    Biochem J; 2004 Jul; 381(Pt 2):343-50. PubMed ID: 15068396
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rit, a non-lipid-modified Ras-related protein, transforms NIH3T3 cells without activating the ERK, JNK, p38 MAPK or PI3K/Akt pathways.
    Rusyn EV; Reynolds ER; Shao H; Grana TM; Chan TO; Andres DA; Cox AD
    Oncogene; 2000 Sep; 19(41):4685-94. PubMed ID: 11032018
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correlation of gene expression of ATP-binding cassette protein and tyrosine kinase signaling pathway in patients with hepatocellular carcinoma.
    Hoffmann K; Shibo L; Xiao Z; Longerich T; Büchler MW; Schemmer P
    Anticancer Res; 2011 Nov; 31(11):3883-90. PubMed ID: 22110214
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Relationship between raf kinase inhibitor protein and metastasis of ovarian carcinoma].
    Wang Y; Yang J; Gao Y; Zhao XL; Li HZ; Yao Z
    Zhonghua Fu Chan Ke Za Zhi; 2009 Jul; 44(7):522-8. PubMed ID: 19957553
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Requirement of activation of the extracellular signal-regulated kinase cascade in myocardial cell hypertrophy.
    Ueyama T; Kawashima S; Sakoda T; Rikitake Y; Ishida T; Kawai M; Yamashita T; Ishido S; Hotta H; Yokoyama M
    J Mol Cell Cardiol; 2000 Jun; 32(6):947-60. PubMed ID: 10888249
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ribonucleotide reductase small subunit p53R2 suppresses MEK-ERK activity by binding to ERK kinase 2.
    Piao C; Jin M; Kim HB; Lee SM; Amatya PN; Hyun JW; Chang IY; You HJ
    Oncogene; 2009 May; 28(21):2173-84. PubMed ID: 19398949
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activation and role of MAP kinase-dependent pathways in retinal pigment epithelial cells: ERK and RPE cell proliferation.
    Hecquet C; Lefevre G; Valtink M; Engelmann K; Mascarelli F
    Invest Ophthalmol Vis Sci; 2002 Sep; 43(9):3091-8. PubMed ID: 12202534
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential effects of kinase cascade inhibitors on neoplastic and cytokine-mediated cell proliferation.
    Shelton JG; Moye PW; Steelman LS; Blalock WL; Lee JT; Franklin RA; McMahon M; McCubrey JA
    Leukemia; 2003 Sep; 17(9):1765-82. PubMed ID: 12970777
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neuroglobin, a novel intracellular hexa-coordinated globin, functions as a tumor suppressor in hepatocellular carcinoma via Raf/MAPK/Erk.
    Zhang J; Lan SJ; Liu QR; Liu JM; Chen XQ
    Mol Pharmacol; 2013 May; 83(5):1109-19. PubMed ID: 23478801
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oncogenic tyrosine kinase NPM/ALK induces activation of the rapamycin-sensitive mTOR signaling pathway.
    Marzec M; Kasprzycka M; Liu X; El-Salem M; Halasa K; Raghunath PN; Bucki R; Wlodarski P; Wasik MA
    Oncogene; 2007 Aug; 26(38):5606-14. PubMed ID: 17353907
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CrkL plays a role in SDF-1-induced activation of the Raf-1/MEK/Erk pathway through Ras and Rac to mediate chemotactic signaling in hematopoietic cells.
    Arai A; Aoki M; Weihua Y; Jin A; Miura O
    Cell Signal; 2006 Dec; 18(12):2162-71. PubMed ID: 16781119
    [TBL] [Abstract][Full Text] [Related]  

  • 18. B-Raf is required for ERK activation and tumor progression in a mouse model of pancreatic beta-cell carcinogenesis.
    Sobczak I; Galabova-Kovacs G; Sadzak I; Kren A; Christofori G; Baccarini M
    Oncogene; 2008 Aug; 27(35):4779-87. PubMed ID: 18490924
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ras mediates radioresistance through both phosphatidylinositol 3-kinase-dependent and Raf-dependent but mitogen-activated protein kinase/extracellular signal-regulated kinase kinase-independent signaling pathways.
    Grana TM; Rusyn EV; Zhou H; Sartor CI; Cox AD
    Cancer Res; 2002 Jul; 62(14):4142-50. PubMed ID: 12124353
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Involvement of p53 and Raf/MEK/ERK pathways in hematopoietic drug resistance.
    McCubrey JA; Abrams SL; Ligresti G; Misaghian N; Wong EW; Steelman LS; Bäsecke J; Troppmair J; Libra M; Nicoletti F; Molton S; McMahon M; Evangelisti C; Martelli AM
    Leukemia; 2008 Nov; 22(11):2080-90. PubMed ID: 18685611
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.